GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that rapidly invades the uterine myometrium and is responsible for 40% of uterine cancer deaths. The molecular mechanisms that underlie this aggressive phenotype are poorly understood. We reported recently that USC tumors with low expression of the zinc-finger transcription factor GATA Binding Protein 2 (GATA2) exhibit aggressive tissue invasion, while retention of GATA2 expression is an independent predictor of 100% recurrence-free and cancer-specific survival in patients with early-stage USC. Here, we explored the mechanism of GATA2 loss in USC tumors that portend invasion. We show that GATA2 in human USC cell lines has a rapid 128-minute protein half-life due to post-translational SUMOylation, which targets GATA2 for ubiquitin-dependent proteasomal degradation. Treatment with small-molecule SUMOylation inhibitors, siRNA-mediated depletion of SUMO-2/3, or mutation of GATA2 K222 and K389 increases GATA2 levels and suppresses invasion in USC cell lines and USC tumor spheroids without impacting cell proliferation or viability. Primary USC tumors from newly diagnosed patients show markedly increased SUMO-2/3 levels and upregulation of SUMOylation pathways compared to other uterine cancer subtypes or benign endometrium, and heat-shock mediated induction of USC SUMO signaling leads to a SUMOylation-dependent reduction in GATA2 levels. Our results implicate SUMOylation as a dynamic regulator of USC GATA2 levels and support a model in which stress-related increases in SUMO activity deplete GATA2 to drive USC invasion. Our findings also raise the possibility that small-molecule SUMOylation inhibitors may benefit patients with early-stage USC disease.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.765417
Primary Topic
Ubiquitin and proteasome pathways
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Daniel R. Matson, Molly A. Accola, Apoorva T. Patil, William M. Rehrauer et al.
3 links
bioRxiv (Cold Spring Harbor Laboratory)
Ubiquitin and proteasome pathways
preprint

GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Daniel R. Matson, Molly A. Accola, Apoorva T. Patil, William M. Rehrauer, Marı́a Virumbrales-Muñoz, Paula M. Mañán-Mejías, Anuoluwapo A Mattix, Finnbar Reed-McBain, Peng Liu, Usha Polaki
preprint en

Abstract

Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that rapidly invades the uterine myometrium and is responsible for 40% of uterine cancer deaths. The molecular mechanisms that underlie this aggressive phenotype are poorly understood. We reported recently that USC tumors with low expression of the zinc-finger transcription factor GATA Binding Protein 2 (GATA2) exhibit aggressive tissue invasion, while retention of GATA2 expression is an independent predictor of 100% recurrence-free and cancer-specific survival in patients with early-stage USC. Here, we explored the mechanism of GATA2 loss in USC tumors that portend invasion. We show that GATA2 in human USC cell lines has a rapid 128-minute protein half-life due to post-translational SUMOylation, which targets GATA2 for ubiquitin-dependent proteasomal degradation. Treatment with small-molecule SUMOylation inhibitors, siRNA-mediated depletion of SUMO-2/3, or mutation of GATA2 K222 and K389 increases GATA2 levels and suppresses invasion in USC cell lines and USC tumor spheroids without impacting cell proliferation or viability. Primary USC tumors from newly diagnosed patients show markedly increased SUMO-2/3 levels and upregulation of SUMOylation pathways compared to other uterine cancer subtypes or benign endometrium, and heat-shock mediated induction of USC SUMO signaling leads to a SUMOylation-dependent reduction in GATA2 levels. Our results implicate SUMOylation as a dynamic regulator of USC GATA2 levels and support a model in which stress-related increases in SUMO activity deplete GATA2 to drive USC invasion. Our findings also raise the possibility that small-molecule SUMOylation inhibitors may benefit patients with early-stage USC disease.

bioRxiv (Cold Spring Harbor Laboratory)
University of Wisconsin–Madison (US), UW Health University Hospital (US)
Wisconsin Alumni Research Foundation, University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center, National Institutes of Health, National Institute of General Medical Sciences, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Office of the Vice Chancellor for Research, University of Illinois at Chicago
Good health and well-being
Ubiquitin and proteasome pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon